Table 1.

Clinical Data of CML Cases.

Information at Time of Sampling							No. of Metaphases Analyzed (Q-FISH)
Samples	Age	Sex	Tissues	Blasts	Karyotype	Clinical Phases
02-H055	45	M	Blood	5%/Blood	46,XY,t(9;22)(q34;q11.2)23	CP	10
02-H058	26	F	Bone marrow	2%/BM	46,XX,t(9;22)(q34;q11.2)21	CP	11
02-H077	45	M	Blood	3%/Blood	46,XY,t(9;22)(q34;q11.2)20	CP	15
03-H034	45	M	Bone marrow	1%/BM	46,XY,t(9;22)(q34;q11.2)19/46,idem,?der(7)del(7)(q11.2q21)del(7)(q36)2	CP	10
03-H044	64	F	Blood	5%/Blood	46,XX,t(9;22)(q34;q11.2)21	CP	15
03-H056	18	M	Blood	3%/Blood	46,XY,t(9;22)(q34;q11.2)21	CP	13
03-H061	44	F	Bone marrow	10%/BM	46,XX,t(9;22)(q34;q11.2)23	AP	15
03-H077	35	F	Bone marrow	5%/BM	46,XX,t(9;22)(q34;q11.2)29	CP	9
03-H079	50	F	Bone marrow	2%/BM	46,XX,t(9;22)(q34;q11.2)20	CP	11
04-H013	52	M	Bone marrow	5%/BM	46,XY,t(9;22)(q34;q11.2)22	CP	5
04-H015	38	F	Bone marrow	3%/BM	46,XX,t(9;22)(q34;q11.2)21	CP	11
04-H035	61	F	Bone marrow	2%/BM	46,XX,t(9;22)(q34;q11.2)20	CP	8
04-H057	44	M	Blood	3%/Blood	46,XY,t(9;22)(q34;q11.2)20	CP	9
04-H131	33	F	Bone marrow	4%/BM	46,XX,t(9;22;13)(q34;q11.2;p13)20	CP	8
05-H020	57	F	Bone marrow	3%/BM	46,XX,t(9;22)(q34;q11.2)20	CP	9
05-H043	45	F	Bone marrow	2%/BM	46,XX,t(9;22)(q34;q11.2)20	CP	10
05-H049	83	F	Bone marrow	2%/BM	46,XX,t(9;22)(q34;q11.2)18	CP	9
05-H166	40	M	Bone marrow	2%/BM	46,XY,t(9;22)(q34;q11.2)20	CP	10
06-H047	39	F	Bone marrow	5%/BM	46,XX,t(9;22)(q34;q11)22	CP	7
06-H069	53	M	Bone marrow	2%/BM	46,XY,t(9;22)(q34.1;q11.2)20	CP	8
06-H097	32	F	Blood	7%/Blood	46,XX,t(9;22)(q34;q11.2)20	CP	9

Samplings were done at diagnosis and before the initiation of treatment. The translocation t(9;22) was the most frequent cytogenetic abnormality. More than 80% of the patients were at the CP, and 13 of 21 patients were females.

AP indicates accelerated phase; CP, chronic phase.